North American Scientific to Host Fiscal First Quarter 2008 Financial Results Conference Call on Wednesday, March 19, 2008

  
    
  
  
    
      North American Scientific, Inc. (Nasdaq: NASI) announced today that it 
      will issue financial results for the first fiscal quarter of 2008, which 
      ended January 31, 2008, at market close on Wednesday, March 19, 
      2008. The Company will host an investor conference call to 
      review its first quarter 2008 financial results and latest corporate 
      developments, beginning at 1:30 p.m. Pacific Time/4:30 p.m. 
      Eastern Time on Wednesday, March 19, 2008. The 
      dial-in number for the conference call is 800-798-2801 for domestic 
      participants and 617-614-6205 for international participants.
    
    
      A live webcast of North American Scientific’s 
      conference call will be available over the Internet through its website 
      at www.nasmedical.com in the 
      Investor Center. For those who cannot listen to the live webcast, a 
      taped replay of the call will be available beginning approximately one 
      hour after the call’s conclusion and will 
      remain available for seven days. It can be accessed at the same site 
      shortly after the call, or by dialing 888-286-8010 for domestic callers 
      and 617-801-6888 for international callers, using the passcode 79158387.
    
    
      About North American Scientific
    
    
      North American Scientific is a leader in radiation therapy in the fight 
      against cancer. Its innovative products provide physicians with tools 
      for the treatment of various types of cancers. They include Prospera® 
      brachytherapy seeds and SurTRAK™ needles and 
      strands used primarily in the treatment of prostate cancer. In addition, 
      the Company has been gaining clinical experience with its first 
      generation ClearPath™ multi-channel catheter 
      breast brachytherapy devices in 2007, and intends to launch the second 
      generation devices in 2008. They are the only such devices approved for 
      both high dose and continuous release, or low dose, radiation 
      treatments. The devices are designed to provide flexible, precise dose 
      conformance and an innovative delivery system that is intended to offer 
      the more advanced form of brachytherapy for the treatment of breast 
      cancer. Please visit www.nasmedical.com 
      for more information.